PLK1 and neoplasm: Moreover, the protein levels of PLK‐1, CCNB1, CCNB2, and SIRT2 were observed to decrease in a dose‐dependent manner in tumor tissues following treatment with VS‐5584 in comparison to the control group (Figure 8D).